These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35062802)

  • 1. Hydroxychloroquine in Treatment of Asymptomatic and Mildly Symptomatic COVID-19: A Multi-Centre Cohort Study.
    Jain S; Sharma SK; Suri V; Yaddanapudi N; Malhotra P; Bhalla A; Singh MP; Koushal V; Kajal K; Jakulla RS; Marrapu S; Guru RR; Bora I; Chopra V; Sibia R; Puri GD
    J Assoc Physicians India; 2022 Jan; 70(1):11-12. PubMed ID: 35062802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease.
    Mallat J; Hamed F; Balkis M; Mohamed MA; Mooty M; Malik A; Nusair A; Bonilla MF
    Medicine (Baltimore); 2020 Dec; 99(52):e23720. PubMed ID: 33350752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial.
    Byakika-Kibwika P; Sekaggya-Wiltshire C; Semakula JR; Nakibuuka J; Musaazi J; Kayima J; Sendagire C; Meya D; Kirenga B; Nanzigu S; Kwizera A; Nakwagala F; Kisuule I; Wayengera M; Mwebesa HG; Kamya MR; Bazeyo W
    BMC Infect Dis; 2021 Dec; 21(1):1218. PubMed ID: 34872511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.
    Bhandari S; Singh A; Sharma R; Rankawat G; Banerjee S; Gupta V; Dube A; Kakkar S; Sharma S; Keswani P; Agrawal A; Tak A; Nawal CL
    J Assoc Physicians India; 2020 Jun; 68(6):13-19. PubMed ID: 32610873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting.
    Mokhtari M; Mohraz M; Gouya MM; Namdari Tabar H; Tabrizi JS; Tayeri K; Aghamohamadi S; Rajabpoor Z; Karami M; Raeisi A; Rahmani H; Khalili H
    Int Immunopharmacol; 2021 Jul; 96():107636. PubMed ID: 34015598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine (HCQ) Treatment for Hospitalized Patients with COVID- 19.
    Tsanovska H; Simova I; Genov V; Kundurzhiev T; Krasnaliev J; Kornovski V; Dimitrov N; Vekov T
    Infect Disord Drug Targets; 2022; 22(6):e030322201650. PubMed ID: 35240966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
    Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.
    Koh HM; Chong PF; Tan JN; Chidambaram SK; Chua HJ
    J Clin Pharm Ther; 2021 Jun; 46(3):800-806. PubMed ID: 33768612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).
    Chen CP; Lin YC; Chen TC; Tseng TY; Wong HL; Kuo CY; Lin WP; Huang SR; Wang WY; Liao JH; Liao CS; Hung YP; Lin TH; Chang TY; Hsiao CF; Huang YW; Chung WS; Cheng CY; Cheng SH;
    PLoS One; 2020; 15(12):e0242763. PubMed ID: 33264337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial.
    Agusti A; Guillen E; Ayora A; Anton A; Aguilera C; Vidal X; Andres C; Alonso M; Espuga M; Esperalba J; Gorgas MQ; Almirante B; Ribera E
    Enferm Infecc Microbiol Clin (Engl Ed); 2022; 40(6):289-295. PubMed ID: 35680347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
    Guner R; Hasanoglu I; Kayaaslan B; Aypak A; Akinci E; Bodur H; Eser F; Kaya Kalem A; Kucuksahin O; Ates I; Bastug A; Tezer Tekce Y; Bilgic Z; Gursoy FM; Akca HN; Izdes S; Erdem D; Asfuroglu E; Hezer H; Kilic H; Cıvak M; Aydogan S; Buzgan T
    J Infect Public Health; 2021 Mar; 14(3):365-370. PubMed ID: 33647553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine.
    Tanaka T; Okamoto M; Matsuo N; Naitou-Nishida Y; Nouno T; Kojima T; Nishii Y; Uchiyashiki Y; Takeoka H; Nagasaki Y
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
    Falcão F; Viegas E; Carmo I; Soares J; Falcao M; Solano M; Cavaco P; Mendes D; Rijo J; Povoa P; Pais Martins A; Carmo E; Mansinho K; Fonseca C; Campos L; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
    Eur J Hosp Pharm; 2021 Sep; 28(5):248-253. PubMed ID: 33452110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
    Dabbous HM; El-Sayed MH; El Assal G; Elghazaly H; Ebeid FFS; Sherief AF; Elgaafary M; Fawzy E; Hassany SM; Riad AR; TagelDin MA
    Sci Rep; 2021 Mar; 11(1):7282. PubMed ID: 33790308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.